On the afternoon of July 6, at the 42nd China Pharmaceutical Industry Information Annual Conference, the "2024 Top 100 Pharmaceutical Companies in China" list was officially released.

Two core companies under the Hong Kong-listed pharmaceutical leader Sino Biopharm were once again both on the list. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. entered the national top 10 for the first time, ranking 9th; Beijing Tide Pharmaceutical ranked 65th, making the list for the 13th consecutive year. Both companies were also named "Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China".

The China Pharmaceutical Industry Information Annual Conference is an annual grand event in the pharmaceutical world. Since its first session in 1959, it has been successfully held 42 times. It has not only witnessed the development journey of China's pharmaceutical industry but also recorded the progress and achievements of pharmaceutical technology innovation in the new era, and is known as the "bellwether of the pharmaceutical industry".

Previously, Chia Tai Tianqing had been listed in the top 20 of the Top 100 Pharmaceutical Companies in China for 10 consecutive years. It is reported that in recent years, under the guidance of its "comprehensive innovation" strategy, Chia Tai Tianqing has continuously deepened its cutting-edge layout in core therapeutic fields including oncology, hepatology, and respiratory through a combination of internal R&D innovation and external diversified cooperation. It has had 8 Class 1 innovative drugs, including Anlotinib, approved for marketing, with nearly 80 innovative projects under development. In the next three years, nearly 20 more innovative products are expected to be launched, including multiple products with First-in-class and Best-in-class potential. At the ASCO Annual Meeting of this year, Chia Tai Tianqing had a total of 12 studies selected for oral presentation, setting a new record for a Chinese pharmaceutical company. Among them, Anlotinib, the "Glory of Chinese Medicine", accounted for 9 presentations, also setting a new record for a Chinese innovative drug. The "Defu Combination" of Anlotinib and Benmelstobart defeated the global blockbuster drug Keytruda in a head-to-head trial, showcasing a "Chinese solution" on the global stage.

Beijing Tide Pharmaceutical is a leading domestic enterprise in the fields of transdermal patches and surgery/analgesia. After more than a decade of technological development, it has successfully established four major technology platforms covering cataplasms, hot-melt adhesive patches, transdermal patches, and microneedling patches. Currently, five patch products have been approved for marketing.

Among them, Flurbiprofen Cataplasms has maintained its position as the number one brand in the topical analgesic market for many consecutive years. This year, its self-developed Tulobuterol Patches and Loxoprofen Sodium Cataplasms were both approved for marketing, used for relieving dyspnoea and for anti-inflammatory analgesia, respectively, bringing new options to domestic patients.

A representative from Sino Biopharm stated that against the backdrop of an accelerating restructuring of the industry ecosystem, the company's two core member enterprises have demonstrated strong competitive vitality in their respective fields through continuous investment in innovation. In the future, the group will continue to focus on its core areas of strength, increase its innovation efforts, and accelerate its transformation into an innovative pharmaceutical enterprise with global competitiveness.